Comparison Between Recombinant Versus Urinary hCG for Ovulation Induction in High Responders
NCT ID: NCT00415766
Last Updated: 2016-01-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
150 participants
INTERVENTIONAL
2013-06-30
2016-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison Between hCG and GnRH Agonist for Ovulation Induction in Patients With High Response to IVF Drugs
NCT00415792
Comparing the Efficacy of Urinary and Recombinant Human Chorionic Gonadotropin (hCG) on Oocyte Maturity
NCT01507376
Pregnancy Rates in IVF After Ovulation Triggering With Recombinant or Urinary Human Chorionic Gonadotrophin (HCG)
NCT00954265
A Study Using Recombinant Human Chorionic Gonadotrophin (rhCG, Ovidrel®) in the Induction of Final Follicle Maturation and Early Luteinization in Chinese Women Undergoing in Vitro Fertilization and Embryo Transfer (IVF/ET)
NCT01081756
Optimal rhCG(Ovidrel®) Dose in Poor Responder During IVF and ICSI Cycles
NCT01406600
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
rHCG 250 ug
Injection of 250 ug Ovitrelle to trigger final oocyte maturation
rHCG 250ug
Injection of 250 ug Ovitrelle to trigger final oocyte maturation
uHCG 5000 IU
Injection of 5000 IU Pregnyl to trigger final oocyte maturation
uHCG 5000 IU
Injection of 5000 IU Pregnyl to trigger final oocyte maturation
uHCG 7500 IU
Injection of 7500 IU Pregnyl to trigger final oocyte maturation
uHCG 7500 IU
Injection of 7500 IU Pregnyl to trigger final oocyte maturation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
rHCG 250ug
Injection of 250 ug Ovitrelle to trigger final oocyte maturation
uHCG 5000 IU
Injection of 5000 IU Pregnyl to trigger final oocyte maturation
uHCG 7500 IU
Injection of 7500 IU Pregnyl to trigger final oocyte maturation
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Pretreated with GnRH antagonist protocol
Exclusion Criteria
* Women with 25 or more follicles on the day of trigger
18 Years
39 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eugonia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tryfon Lainas, PhD
Role: PRINCIPAL_INVESTIGATOR
Eugonia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Eugonia
Athens, , Greece
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Revelli A, Poso F, Gennarelli G, Moffa F, Grassi G, Massobrio M. Recombinant versus highly-purified, urinary follicle-stimulating hormone (r-FSH vs. HP-uFSH) in ovulation induction: a prospective, randomized study with cost-minimization analysis. Reprod Biol Endocrinol. 2006 Jul 18;4:38. doi: 10.1186/1477-7827-4-38.
Al-Inany HG, Aboulghar M, Mansour R, Proctor M. Recombinant versus urinary human chorionic gonadotrophin for ovulation induction in assisted conception. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003719. doi: 10.1002/14651858.CD003719.pub2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ovitrelle vs pregnyl
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.